Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bindarit in Preventing Stent Restenosis
NCT01269242Phase 2Completed
- Sponsor
- Angelini Pharma
- Start
- Jan 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bindarit in coronary restenosis (3 arms), sponsored by Angelini Pharma. Primary endpoint: In-segment late loss measured by QCA at 6 months. Started Jan 2009; status: completed.
02
Drugs
bindarit
03
Conditions
coronary restenosis
Beyond the preview
Go deeper on NCT01269242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01269242.